JPWO2019246356A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019246356A5 JPWO2019246356A5 JP2020570938A JP2020570938A JPWO2019246356A5 JP WO2019246356 A5 JPWO2019246356 A5 JP WO2019246356A5 JP 2020570938 A JP2020570938 A JP 2020570938A JP 2020570938 A JP2020570938 A JP 2020570938A JP WO2019246356 A5 JPWO2019246356 A5 JP WO2019246356A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- antigen
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940125555 TIGIT inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- -1 cancer vaccines Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| US62/688,251 | 2018-06-21 | ||
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528423A JP2021528423A (ja) | 2021-10-21 |
| JPWO2019246356A5 true JPWO2019246356A5 (pt) | 2022-06-23 |
| JP7403480B2 JP7403480B2 (ja) | 2023-12-22 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570938A Active JP7403480B2 (ja) | 2018-06-21 | 2019-06-20 | 二重特異性抗ｃｄ３×ｍｕｃ１６抗体および抗ｐｄ－１抗体で癌を治療する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (pt) |
| EP (2) | EP4424712A2 (pt) |
| JP (1) | JP7403480B2 (pt) |
| KR (1) | KR20210023981A (pt) |
| CN (1) | CN112312970A (pt) |
| AU (1) | AU2019290170A1 (pt) |
| BR (1) | BR112020025476A2 (pt) |
| CA (1) | CA3103887A1 (pt) |
| CL (1) | CL2020003256A1 (pt) |
| DK (1) | DK3810281T3 (pt) |
| EA (1) | EA202190088A1 (pt) |
| FI (1) | FI3810281T3 (pt) |
| IL (1) | IL279251A (pt) |
| MA (1) | MA52962A (pt) |
| MX (1) | MX2020013905A (pt) |
| PH (1) | PH12020552115A1 (pt) |
| PT (1) | PT3810281T (pt) |
| RS (1) | RS65886B1 (pt) |
| SG (1) | SG11202012137UA (pt) |
| TW (1) | TW202005985A (pt) |
| WO (1) | WO2019246356A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| JP2021535142A (ja) | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
| EP4284512A1 (en) | 2021-01-28 | 2023-12-06 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| JPWO2023033022A1 (pt) | 2021-08-31 | 2023-03-09 | ||
| AU2022398486A1 (en) * | 2021-11-24 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| KR20240130137A (ko) * | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
| TW202334234A (zh) | 2022-01-10 | 2023-09-01 | 大陸商南京維立志博生物科技有限公司 | 一種抗體及其用途 |
| TW202400232A (zh) * | 2022-03-16 | 2024-01-01 | 日商第一三共股份有限公司 | 多特異性分子與免疫檢查點抑制劑之組合 |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3353212B1 (en) * | 2015-09-23 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
| RS64588B1 (sr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| WO2018067331A1 (en) * | 2016-09-23 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates |
| BR112019010878A2 (pt) * | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW108121196A patent/TW202005985A/zh unknown
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en active Application Filing
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 KR KR1020217000649A patent/KR20210023981A/ko unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 MA MA052962A patent/MA52962A/fr unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170A1/en active Pending
- 2019-06-20 EP EP24176671.6A patent/EP4424712A2/en active Pending
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970A/zh active Pending
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
-
2020
- 2020-12-07 IL IL279251A patent/IL279251A/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050618A5 (pt) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2019515008A5 (pt) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2019519499A5 (pt) | ||
| JP2020515247A5 (pt) | ||
| JP2020534250A5 (pt) | ||
| JP2021518103A5 (pt) | ||
| JP2020508317A5 (pt) | ||
| RU2017121327A (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| JPWO2019246514A5 (pt) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020515577A5 (pt) | ||
| KR20220028177A (ko) | 류마티스 관절염에 대한 치료 | |
| JPWO2019246356A5 (pt) | ||
| JP2020522280A5 (pt) | ||
| US20220213203A1 (en) | Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| WO2020049534A1 (en) | Sting agonist and combination therapy thereof for the treatment of cancer | |
| JPWO2020232019A5 (pt) | ||
| RU2024117128A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4 | |
| WO2022057910A1 (en) | Combination therapies targeting c5ar and pd-1/pd-l1 pathways | |
| JPWO2021113701A5 (pt) |